Asclera Polidocanol Injections Now FDA Approved for US Vein Therapies

The North Shore Vein Center is pleased to announce the addition of newly FDA approved Polidocanol.

ASCLERA_logo_121609-300x96Polidocanol (Asclera) got U.S. FDA approval in March 2010 for the treatment of small varicose veins. Specifically, Polidocanol is approved to close spider veins (<1 mm in diameter) and reticular veins (1 – 3 mm in diameter).

Polidocanol creates fibrosis within the cell lining of blood vessels, causing them to collapse; the vein is then eventually replaced by other types of tissue. This is not a new sclerosant for varicose veins; it has been used for decades in Europe. Polidocanol is the #1 scleroscent worldwide and the eventual introduction to the U.S. market is long welcomed.

It may produce less “shadowing” on the skin after treatment. Polidocanol is a bit of an anesthetic as well, so for injection purposes, it is less painful and there are reportedly less side effects.

Asclera was evaluated in a multicenter, randomized, double-blind study in patients with spider or reticular veins. As rated by physicians, Asclera showed good or complete response in 95% of treated patients. On average, 86% of patients were satisfied or very satisfied with their Asclera treatment.